Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy
Rina Nishii(Tokyo Medical and Dental University), Takaya Moriyama(St. Jude Children's Research Hospital), Laura J. Janke(St. Jude Children's Research Hospital), Wenjian Yang(St. Jude Children's Research Hospital), Chase C. Suiter(St. Jude Children's Research Hospital), Ting-Nien Lin(St. Jude Children's Research Hospital), Lie Li(St. Jude Children's Research Hospital), Kentaro Kihira(Mie University), Hidemi Toyoda(Mie University), Ute Hofmann(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Matthias Schwab(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Masatoshi Takagi(Tokyo Medical and Dental University), Tomohiro Morio(Tokyo Medical and Dental University), Atsushi Manabe(St. Luke's International Hospital), Shirley Kow Yin Kham(National University Hospital), Nan Jiang(National University Hospital), Karen R. Rabin(Baylor College of Medicine), Motohiro Kato(National Center For Child Health and Development), Katsuyoshi Koh(Saitama Children's Medical Center), Allen Eng Juh Yeoh(National University of Singapore), Hiroki Hori(Mie University), Jun J. Yang(St. Jude Children's Research Hospital)
Cited by 56Open Access
Abstract
Key Points We established a Nudt15 knockout mouse model with which to evaluate individualized thiopurine therapy. Preemptive NUDT15 genotype–guided thiopurine dosing can effectively prevent drug toxicity without compromising antileukemic efficacy.
Related Papers
No related papers found
Powered by citation graph analysis